Top

Published in:

01-08-2019 | Prostatectomy | Urology - Original Paper

Index tumor volume on MRI as a predictor of clinical and pathologic outcomes following radical prostatectomy

Authors: Dordaneh Sugano, Abhinav Sidana, Amit L. Jain, Brian Calio, Sonia Gaur, Mahir Maruf, Maria Merino, Peter Choyke, Baris Turkbey, Bradford J. Wood, Peter A. Pinto

Published in: International Urology and Nephrology | Issue 8/2019

Abstract

Purpose

Index tumor volume (ITV) measured on radical prostatectomy (RP) specimens has been shown to be associated with adverse pathologic and oncologic outcomes. We evaluate the value of ITV calculated from prostate multiparametric MRI (mpMRI) in predicting adverse clinical and pathologic outcomes.

Materials and methods

Data from a prospectively maintained, single-institution database were analyzed for patients who underwent mpMRI prior to RP (2007–2016). Index tumor was defined as a T2-visible lesion with the longest diameter. Adverse pathologic outcomes were extraprostatic extension (EPE), lymph node invasion (LNI), seminal vesicle invasion (SVI), and positive margins (PM). Logistic and Cox proportional hazard regression were used to assess associations with adverse pathology and biochemical recurrence (BCR), respectively.

Results

Of the 455 patients included, EPE, LNI, SVI and PM were present in 23.5%, 6.2%, 5.5% and 15.7% patients, respectively. Patients with adverse pathologic outcomes had larger median ITV. ITV was found to be an independent predictor of EPE (OR 1.22, p = 0.010), LNI (OR 1.39, p = 0.001), and SVI (OR 1.28, p = 0.009), but not PM (OR 1.03, p = 0.522). Combination of ITV and PSA was found to have predictive ability comparable to that of modified Partin tables (EPE:ITV + PSA_AUC = 0.71 vs. Partin_AUC = 0.71; LNI:ITV + PSA_AUC = 0.92 vs. Partin_AUC = 0.90, SVI:ITV + PSA_AUC = 0.78 vs. Partin_AUC = 0.82). 5 year BCR-free survival (median follow-up 24.9 months) was higher for patients with ITV < 2 cc (84.1% vs. 58.5%, p = 0.001). However, ITV was not found to be an independent predictor of BCR (HR 1.69, p = 0.130).

Conclusions

We demonstrate that ITV measured on mpMRI is a predictor of adverse pathologic and clinical outcomes and can aid in preoperative risk assessment.

Knoedler JJ, Karnes RJ, Thompson RH et al (2014) The association of tumor volume with mortality following radical prostatectomy. Prostate Cancer Prostatic Dis 17:144–148CrossRefPubMed

Wysock JS, Mendhiratta N, Zattoni F et al (2016) Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results. BJU Int 118:515–520CrossRefPubMed

Turkbey B, Mani H, Aras O et al (2012) Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol 188:1157–1163CrossRefPubMedPubMedCentral

Villers A, Puech P, Mouton D et al (2006) Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 176:2432–2437CrossRefPubMed

Turkbey B, Pinto PA, Mani H et al (2010) Prostate cancer: value of multiparametric MR imaging at 3 T for detection–histopathologic correlation. Radiology 255:89–99CrossRefPubMedPubMedCentral

Institute JH-JBBU (2012) Partin tables. https://www.hopkinsmedicine.org/brady-urology-institute/specialties/conditions-and-treatments/prostate-cancer/fighting-prostate-cancer/partin-table.html. Accessed 23 Mar 2012

Cookson MS, Aus G, Burnett AL et al (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177:540–545CrossRefPubMed

Meyer CP, Hansen J, Boehm K et al (2016) Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. World J Urol 35(2):199–206CrossRefPubMed

Merrill MM, Lane BR, Reuther AM et al (2007) Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer. Urology 70:294–298CrossRefPubMed

10.

Jung JW, Lee JK, Hong SK et al (2015) Stratification of patients with intermediate-risk prostate cancer. BJU Int 115:907–912CrossRefPubMed

11.

Beauval JB, Ploussard G, Cabarrou B et al (2016) Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. World J Urol 35(8):1191–1197CrossRefPubMed

12.

Somford DM, Hamoen EH, Futterer JJ et al (2013) The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol 190:1728–1734CrossRefPubMed

13.

Pelzer AE, Colleselli D, Bektic J et al (2008) Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference? BJU Int 101:822–825CrossRefPubMed

14.

Nakanishi H, Troncoso P, Babaian RJ (2008) Prediction of extraprostatic extension in men with biopsy Gleason score of 8 or greater. J Urol 180:2441–2445 (discussion 2445-6) CrossRefPubMed

15.

Chun FK, Briganti A, Jeldres C et al (2007) Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer 43:536–543CrossRefPubMed

16.

Kongnyuy M, Sidana A, George AK et al (2017) Tumor contact with prostate capsule on magnetic resonance imaging: a potential biomarker for staging and prognosis. Urol Oncol 35:30.e1–30.e8CrossRef

17.

Abdollah F, Abdo A, Sun M et al (2013) Pelvic lymph node dissection for prostate cancer: adherence and accuracy of the recent guidelines. Int J Urol 20:405–410CrossRefPubMed

18.

Briganti A, Gallina A, Nazareno S et al (2013) 374 External validation of the eau guidelines for pelvic lymph node dissection among patients treated with robotic assisted radical prostatectomy. J Urol 189:e151–e152

19.

Yossepowitch O, Briganti A, Eastham JA et al (2014) Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol 65:303–313CrossRefPubMed

20.

Boorjian SA, Karnes RJ, Crispen PL et al (2010) The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol 183:1003–1009CrossRefPubMed

21.

Chalfin HJ, Dinizo M, Trock BJ et al (2012) Impact of surgical margin status on prostate-cancer-specific mortality. BJU Int 110:1684–1689CrossRefPubMed

22.

Preston MA, Blute ML (2014) Positive surgical margins after radical prostatectomy: does it matter? Eur Urol 65:314–315CrossRefPubMed

23.

Novara G, Ficarra V, Mocellin S et al (2012) Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol 62:382–404CrossRefPubMed

24.

Ho R, Siddiqui MM, George AK et al (2016) Preoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical Prostatectomy. PLoS One 11:e0157313CrossRefPubMedPubMedCentral

25.

Meng Y, Li H, Xu P et al (2015) Do tumor volume, percent tumor volume predict biochemical recurrence after radical prostatectomy? A meta-analysis. Int J Clin Exp Med 8:22319–22327PubMedPubMedCentral

26.

Bhindi B, Mamdani M, Kulkarni GS et al (2015) Impact of the U.S. preventive services task force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. J Urol 193:1519–1524CrossRefPubMed

27.

Banerji JS, Wolff EM, Massman JD et al (2016) Prostate needle biopsy outcomes in the Era of the U.S. preventive services task force recommendation against prostate specific antigen based screening. J Urol 195:66–73CrossRefPubMed

28.

Klotz L, Vesprini D, Sethukavalan P et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272–277CrossRefPubMed

Title: Index tumor volume on MRI as a predictor of clinical and pathologic outcomes following radical prostatectomy
Authors: Dordaneh Sugano
Abhinav Sidana
Amit L. Jain
Brian Calio
Sonia Gaur
Mahir Maruf
Maria Merino
Peter Choyke
Baris Turkbey
Bradford J. Wood
Peter A. Pinto
Publication date: 01-08-2019
Publisher: Springer Netherlands
Keywords: Prostatectomy
Prostatectomy
Published in: International Urology and Nephrology / Issue 8/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-019-02168-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Index tumor volume on MRI as a predictor of clinical and pathologic outcomes following radical prostatectomy

Abstract

Purpose

Materials and methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2019

Procedures used for correction of isolated penile torsion: are they competitive or complementary?

Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience

Frailty as a prognostic indicator in the radical cystectomy population: a review

Intradetrusor injection of botulinum toxin A in children: a 10-year single centre experience

Translation, cross-cultural adaptation and validation of the underactive bladder questionnaire to portuguese

Response to the letter to editor: 24-h urine osmolality should be used in combination with other urine parameters in urolithiasis patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page